Certain diabetes drugs linked to lower risk of major heart problems : BMJ

▴ Certain diabetes drugs linked to lower risk of major heart problems : BMJ
In a major breakthrough reserachers found Diadetes drug effective for controlling heart diseases

Drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with a lower risk of major heart problems in patients with type 2 diabetes than dipeptidyl peptidase-4 (DPP-4) inhibitors, finds a study published by The BMJ today.

The researchers say short term use of SGLT2 inhibitors was associated with a decreased risk of cardiovascular events among people with type 2 diabetes, although further studies are needed to determine if these benefits persist long term.

Previous trials have shown that SGLT2 inhibitors can reduce the risk of heart conditions such as heart attack, stroke, and heart failure compared with placebo.

But some of these trials had important limitations, making it difficult to interpret the results, and data on the effects of individual SGLT2 inhibitors on the heart are limited.

So a Canadian team of researchers set out to compare the risk of cardiovascular events between SGLT2 inhibitors and DPP-4 inhibitors among adults with type 2 diabetes in a “real world” clinical practice setting.

Their findings are based on healthcare data from seven Canadian provinces and the United Kingdom from 2013-18 (a total of 209,867 new users of an SGLT2 inhibitor matched to 209,867 users of a DPP-4 inhibitor).

Major cardiovascular events (a combination of heart attack, stroke or cardiovascular death), as well as heart failure and death from any cause (“all-cause mortality”), were recorded for an average of 11 months.

Compared with DPP-4 inhibitors, SGLT2 inhibitors were associated with a reduced risk of heart attack, stroke or cardiovascular death combined (11.4 events per 1000 person-years versus 16.5 events per 1000 person-years).

SGLT2 inhibitors were also associated with decreased risks of individual events. For example, heart attack (5.1 v 6.4 events per 1000 person-years), cardiovascular death (3.9 v 7.7 events per 1000 person-years), heart failure (3.1 v 7.7 events per 1000 person-years), and all-cause mortality (8.7 v 17.3 events per 1000 person-years).

However, SGLT2 inhibitors had more modest benefits for stroke (2.6 v 3.5 events per 1000 person-years).

Results were similar in subgroups defined by patient age, sex, past insulin use, and history of cardiovascular disease.

This is an observational study, so can’t establish cause, and the researchers point to some limitations, such as relying on prescription data over a relatively short follow-up period. What’s more, they cannot rule out the possibility that other unmeasured (confounding) factors may have affected their results.

However, results were consistent across several analyses, suggesting that they withstand scrutiny.

As such, they say these findings suggest that SGLT2 inhibitors “offer cardioprotective benefits among people with type 2 diabetes in a real-world setting, although additional studies are needed to determine if these benefits persist long term.”

Tags : #BMJ #DiabetesDrugs #SodiumGlucoseCotransporter #SGLT2forControllingHeartDiseases #LatestBMJResearchSep25 #DiabetesDrugControlsHeartDiseases

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024